Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXSNASDAQ:FBRXNASDAQ:MDWDNASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXSAstria Therapeutics$4.95+13.3%$4.59$3.56▼$12.92$279.35M0.45373,371 shs795,541 shsFBRXForte Biosciences$8.38-13.3%$7.08$4.11▼$28.68$55.17M2.82157,860 shs46,467 shsMDWDMediWound$21.34+1.2%$17.68$12.78▼$24.00$230.64M0.391,022 shs46,524 shsSLDBSolid Biosciences$3.30+1.2%$3.15$2.41▼$10.37$255.80M2.321.08 million shs734,092 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXSAstria Therapeutics+6.85%+11.48%-11.90%-30.74%-51.71%FBRXForte Biosciences-16.13%+36.01%+35.81%+3.98%+37,035.18%MDWDMediWound-1.13%+5.98%+15.25%+29.88%+18.49%SLDBSolid Biosciences+7.24%+20.74%+0.93%-38.84%-56.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXSAstria Therapeutics1.7931 of 5 stars3.61.00.00.02.61.70.0FBRXForte Biosciences2.9658 of 5 stars3.53.00.00.02.71.71.3MDWDMediWound1.9312 of 5 stars3.52.00.00.02.10.80.6SLDBSolid Biosciences3.9132 of 5 stars4.61.00.00.02.94.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXSAstria Therapeutics 3.25Buy$30.00506.06% UpsideFBRXForte Biosciences 3.00Buy$32.50287.83% UpsideMDWDMediWound 3.00Buy$31.2546.44% UpsideSLDBSolid Biosciences 3.23Buy$14.90351.52% UpsideCurrent Analyst Ratings BreakdownLatest FBRX, ATXS, MDWD, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.00 ➝ $31.005/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.005/16/2025SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.005/16/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.005/14/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.005/13/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/2/2025MDWDMediWoundAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/29/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$47.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXSAstria TherapeuticsN/AN/AN/AN/A$3.33 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$24.30 per shareN/AMDWDMediWound$19.21M12.00N/AN/A$3.43 per share6.22SLDBSolid Biosciences$8.09M31.62N/AN/A$6.27 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXSAstria Therapeutics-$72.89M-$1.87N/AN/AN/AN/A-43.58%-29.36%8/11/2025 (Estimated)FBRXForte Biosciences-$31.48M-$16.29N/AN/AN/AN/A-151.43%-118.92%8/13/2025 (Estimated)MDWDMediWound-$6.72M-$2.09N/AN/AN/A-142.29%-82.17%-33.67%8/13/2025 (Estimated)SLDBSolid Biosciences-$96.01M-$2.99N/AN/AN/AN/A-58.75%-47.84%8/12/2025 (Estimated)Latest FBRX, ATXS, MDWD, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MDWDMediWound-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million5/15/2025Q1 2025FBRXForte Biosciences-$0.89-$1.37-$0.48-$1.37N/AN/A5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/13/2025Q1 2025ATXSAstria Therapeutics-$0.48-$0.58-$0.10-$0.58N/AN/A3/19/2025Q4 2024MDWDMediWound-$0.59-$0.36+$0.23-$0.36$5.79 million$5.84 million3/11/2025Q4 2024ATXSAstria Therapeutics-$0.45-$0.44+$0.01-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXSAstria TherapeuticsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXSAstria TherapeuticsN/A22.3822.38FBRXForte BiosciencesN/A2.062.06MDWDMediWoundN/A2.111.99SLDBSolid BiosciencesN/A7.857.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXSAstria Therapeutics98.98%FBRXForte Biosciences77.63%MDWDMediWound46.83%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipATXSAstria Therapeutics2.90%FBRXForte Biosciences5.90%MDWDMediWound9.20%SLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXSAstria Therapeutics3056.43 million54.80 millionOptionableFBRXForte Biosciences56.58 million6.20 millionOptionableMDWDMediWound8010.81 million9.79 millionOptionableSLDBSolid Biosciences10077.52 million35.05 millionOptionableFBRX, ATXS, MDWD, and SLDB HeadlinesRecent News About These CompaniesSolid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthroughMay 28 at 2:49 PM | investing.comSolid Biosciences to Participate at the Jefferies Global Healthcare ConferenceMay 28 at 8:00 AM | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by BrokeragesMay 28 at 1:31 AM | marketbeat.comResearch Analysts Set Expectations for SLDB FY2025 EarningsMay 27 at 1:50 AM | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor FitzgeraldMay 24, 2025 | marketbeat.comChardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock PriceMay 21, 2025 | marketbeat.comQ1 Earnings Forecast for SLDB Issued By William BlairMay 21, 2025 | marketbeat.comWedbush Cuts Solid Biosciences (NASDAQ:SLDB) Price Target to $17.00May 19, 2025 | americanbankingnews.comBarclays Cuts Solid Biosciences (NASDAQ:SLDB) Price Target to $10.00May 19, 2025 | americanbankingnews.comTruist maintains buy on Solid Biosciences stock, price target at $16May 18, 2025 | investing.comDimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)May 18, 2025 | marketbeat.comWhen Might Solid Biosciences Run Out Of Money?May 17, 2025 | finance.yahoo.comSolid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" RatingMay 17, 2025 | marketbeat.comSolid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 16, 2025 | finanznachrichten.deSolid Biosciences (SLDB) Expected to Announce Earnings on WednesdayMay 16, 2025 | marketbeat.comSolid Biosciences files for $400M mixed securities shelf offeringMay 16, 2025 | msn.comSolid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 15, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by BrokeragesMay 4, 2025 | marketbeat.comWhy Solid Biosciences Inc.’s (SLDB) Stock Is Up 10.82%May 3, 2025 | aaii.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comSolid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual MeetingMay 1, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBRX, ATXS, MDWD, and SLDB Company DescriptionsAstria Therapeutics NASDAQ:ATXS$4.95 +0.58 (+13.27%) Closing price 04:00 PM EasternExtended Trading$5.06 +0.11 (+2.22%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Forte Biosciences NASDAQ:FBRX$8.38 -1.29 (-13.34%) Closing price 04:00 PM EasternExtended Trading$8.48 +0.09 (+1.13%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.MediWound NASDAQ:MDWD$21.34 +0.26 (+1.23%) Closing price 04:00 PM EasternExtended Trading$21.32 -0.02 (-0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Solid Biosciences NASDAQ:SLDB$3.30 +0.04 (+1.23%) Closing price 04:00 PM EasternExtended Trading$3.28 -0.02 (-0.76%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
